Quick answer
What is semaglutide? Semaglutide is a synthetic analog of human glucagon-like peptide-1 (GLP-1), built on the 31-residue GLP-1(7-37) backbone, with the formula C187H291N45O59. Relative to the native peptide it carries two amino acid substitutions (Aib at position 8 and Arg at position 34) and a fatty-diacid chain attached through a spacer to lysine 26. The substitutions and derivatization were designed for stability against metabolic degradation and high albumin affinity. In the original discovery paper, semaglutide had a GLP-1 receptor affinity of 0.38 nM and a plasma half-life of 46.1 hours in mini-pigs. In the laboratory it serves as a reference agonist of the GLP-1 receptor. This guide is for laboratory research use only; not for human consumption.
A flat definition of semaglutide misses the point of the molecule. It is the product of a series of design decisions made over decades, each one solving a specific problem that the previous molecule left open. Seen as a family tree, the structure makes sense, and so does the way researchers use it. The articles on semaglutide research and what is Sema cover other angles; here the organizing idea is lineage.
The root: native GLP-1
The family begins with a hormone. Mojsov and colleagues, writing in 1987, reported that a glucagon-like peptide co-encoded with glucagon in the proglucagon gene is a potent stimulator of insulin secretion. They described two forms, GLP-I(1-37) and GLP-I(7-37), and tested synthetic versions in the isolated perfused rat pancreas. In the presence of 6.6 mM glucose, GLP-I(7-37) was a potent stimulator at concentrations as low as 5 × 10⁻¹¹ M, giving 3- to 10-fold increases over basal, whereas GLP-I(1-37) had no effect even at 5 × 10⁻⁷ M.
Two things from this foundational result matter later. First, the active species is the truncated 31-residue GLP-1(7-37), and that is the backbone semaglutide keeps. Second, the native peptide is a short-acting signal. The physiology of that signal is reviewed in Holst's article on the physiology of glucagon-like peptide 1, and the later discovery paper for semaglutide frames the design goal as increasing albumin affinity while securing full stability against metabolic degradation, which is the gap that native GLP-1 leaves.
A branch from venom: exendin-4
A second branch comes from an unexpected source. Eng and colleagues isolated a 39-amino-acid peptide, exendin-4, from the venom of Heloderma suspectum, the Gila monster. It differs from exendin-3 (from Heloderma horridum) by two substitutions. In guinea pig pancreatic acini, exendin-4 stimulated a rise in cAMP beginning at 100 pM, plateauing at 10 nM, and the response was inhibited by the exendin receptor antagonist exendin-(9-39) amide. Göke and colleagues later reported that exendin-4 is a high-potency agonist and exendin-(9-39)-amide an antagonist at the GLP-1 receptor of insulin-secreting beta-cells.
The exendin branch matters to semaglutide for a conceptual reason: it showed that a peptide quite unlike GLP-1 in sequence could act as a GLP-1 receptor agonist, which widened the set of sequences considered when designing analogs of GLP-1 itself.
The first engineered branch: liraglutide
The semaglutide story starts, in the authors' own account, from liraglutide. In the Lau discovery paper, liraglutide is described as an acylated GLP-1 analog that binds serum albumin in vivo. The stated goal of the study was to design a once-weekly GLP-1 analogue by increasing albumin affinity and securing full stability against metabolic degradation. The fatty acid moiety and the chemistry linking it to GLP-1 were the key features that determined albumin affinity and receptor potency. The review by Knudsen and Lau, "The Discovery and Development of Liraglutide and Semaglutide," charts the same path and states that reversible binding to albumin was used for the systemic protraction of both molecules, with optimal fatty-acid and linker combinations identified to maximize albumin binding while keeping receptor potency.
The principle is worth stating in one sentence: a fatty acid on the peptide lets it ride on albumin, a large protein with a long circulating life, and release from it slowly. The same principle is explained for amylin-family peptides in the cagrilintide overview, which carries a similar lipid modification.
The newest branch: semaglutide
Per the Lau paper's abstract, semaglutide was selected as the optimal once-weekly candidate. It has two amino acid substitutions compared with human GLP-1, Aib8 and Arg34, and is derivatized at lysine 26. Its GLP-1 receptor affinity (0.38 ± 0.06 nM) was three-fold lower than that of liraglutide, while its albumin affinity was higher. After intravenous administration in mini-pigs, the plasma half-life was 46.1 hours, and the mean residence time after subcutaneous administration was 63.6 hours. Those are numbers reported for an animal species in a discovery paper; they describe the compound's design performance in that model.
| Family member | Origin | Key feature reported | Source |
|---|---|---|---|
| GLP-1(7-37) | Natural hormone, proglucagon-derived | 31 residues; stimulated insulin secretion in perfused rat pancreas at 5 × 10⁻¹¹ M | Mojsov 1987 |
| Exendin-4 | Heloderma suspectum venom | 39 residues; acts through the exendin/GLP-1 receptor; high potency | Eng 1992; Göke 1993 |
| Liraglutide | Engineered, acylated GLP-1 analog | Albumin binding in vivo | Lau 2015; Knudsen 2019 |
| Semaglutide | Engineered; Aib8, Arg34, Lys26 derivatized | Higher albumin affinity than liraglutide; 46.1 h plasma half-life in mini-pigs | Lau 2015 |
The receptor end: what semaglutide binds
All the family members converge on one receptor. The GLP-1 receptor is a class B G protein-coupled receptor that signals mainly through Gs and cAMP. Zhang and colleagues reported cryo-EM structures and 3D variability analysis of semaglutide- and taspoglutide-bound GLP-1R–Gs complexes. They found peptide interactions similar to those of GLP-1 but different motions within the receptor and the bound peptides, which they offer as insight into the molecular determinants of GLP-1R peptide engagement. This is the structural reason semaglutide is used as a reference agonist: its interaction with a single, well-mapped receptor has been described down to the level of receptor motion.
What the vial is and how it is used
The semaglutide product page lists a 10 mg vial of lyophilized powder, ≥98% purity by HPLC, the formula C187H291N45O59, and a sealed clear glass research vial, with the sequence and identity reported on the certificate of analysis where published. Research applications named there are GLP-1 receptor signaling research, receptor-activation assay models and receptor-binding studies. The page gives storage as refrigerated at 2–8 °C, −20 °C for long-term, and protected from heat, moisture and light. Because the molecule is an acylated peptide that sticks to surfaces and foams, handling is covered separately in semaglutide reconstitution and handling and storage and stability.
| Bench use | Why semaglutide suits it |
|---|---|
| GLP-1R binding and activation assays | Single-receptor mechanism with a defined cryo-EM structure |
| Comparison against dual or triple agonists | Serves as the single-agonist baseline, as in semaglutide versus tirzepatide |
| Chromatography method development | A well-characterized acylated peptide with a known formula and mass |
| Albumin-binding studies | Textbook example of half-life extension through a fatty-diacid side chain |
Reading the lineage as a design lesson
The four-step history shows how peptide engineering generally works. A hormone is identified and its active fragment defined. A second source, here venom, shows what a degradation-resistant agonist can look like. Chemists then add stability-oriented substitutions (Aib, Arg) and protraction (a fatty acid on a linker), and measure the result by affinity, albumin binding and animal pharmacokinetics. Broader reviews of peptide drug discovery, such as Muttenthaler and colleagues' perspective on trends in the field, describe the same pattern across many peptide classes: start from a human hormone, then use medicinal chemistry to fix its liabilities. For research, the practical consequence is that semaglutide behaves differently from native GLP-1 in assays, so a buffer or incubation time chosen for the native peptide may not carry over without testing.
Practical checks before an experiment
Concentration of a stock is mass divided by volume, so the vial mass and the diluent volume fix it exactly; the reconstitution calculator does the arithmetic and any serial dilutions. Compare the lot number on the vial with the entry in the COA library, and use how to read a COA to interpret the fields. Quality checks that go beyond a label are described in semaglutide purity testing. For the wider incretin field, see GLP-1 receptor agonists in research, and browse other compounds in the catalog.
Frequently asked questions
What is semaglutide in simple terms?
A laboratory analog of human GLP-1, built on its 31-residue active backbone, modified for stability against metabolic degradation and high albumin affinity. It is used as a reference agonist for the GLP-1 receptor.
How does semaglutide differ from native GLP-1?
It has Aib at position 8 and Arg at position 34, and a fatty-diacid chain on lysine 26 attached through a spacer. The design aim, per the discovery paper, was albumin affinity plus full stability against metabolic degradation.
Where does the name GLP-1 come from?
Glucagon-like peptide-1 is one of the peptides liberated from proglucagon, the same precursor that yields glucagon. Mojsov and colleagues described GLP-I(7-37) as co-encoded in the glucagon gene.
Is exendin-4 the same as semaglutide?
No. Exendin-4 is a 39-residue peptide from Gila monster venom that acts as a GLP-1 receptor agonist. Semaglutide is an engineered GLP-1 analog. They are different molecules that act on the same receptor.
What did the discovery paper report for semaglutide?
A GLP-1 receptor affinity of 0.38 ± 0.06 nM, higher albumin affinity than liraglutide, a 46.1 h plasma half-life after intravenous administration in mini-pigs and a 63.6 h mean residence time after subcutaneous administration in the same species.
What receptor does semaglutide act on?
The GLP-1 receptor, a class B G protein-coupled receptor signaling mainly through Gs and cAMP. Cryo-EM structures of semaglutide-bound GLP-1R–Gs complexes have been published.
What does the V8 product page list for semaglutide?
A 10 mg lyophilized vial, ≥98% purity by HPLC, formula C187H291N45O59, in a sealed clear glass research vial, with sequence and identity reported on the certificate of analysis where published.
How should the lyophilized vial be stored?
The page states refrigerate at 2–8 °C, −20 °C for long-term, and protect from heat, moisture and light.
Why does semaglutide foam or stick to plastic?
The fatty side chain makes the molecule amphiphilic, so it favors air–water and plastic surfaces. Gentle swirling, low-binding labware and minimal transfers limit loss.
Why is semaglutide used as a comparator for other incretin agonists?
Because it acts through one receptor that is thoroughly mapped, so differences seen with dual or triple agonists can be attributed to their additional receptor activity.
All material discussed is supplied for laboratory research use only; not for human consumption.
Related reading: Semaglutide Research Update: 2025–2026 Preclinical Papers, Semaglutide Animal Models: Choosing a Species, Semaglutide Cardiovascular Research: Preclinical Models.
References
- Mojsov S, Weir GC, Habener JF. Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest. 1987;79(2):616-619. doi:10.1172/JCI112855
- Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. J Biol Chem. 1992;267(11):7402-7405. PMID: 1313797
- Göke R, et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem. 1993;268(26):19650-19655. PMID: 8396143
- Lau J, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370-7380. doi:10.1021/acs.jmedchem.5b00726
- Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol. 2019;10:155. doi:10.3389/fendo.2019.00155
- Zhang X, et al. Structure and dynamics of semaglutide- and taspoglutide-bound GLP-1R-Gs complexes. Cell Rep. 2021;36(6):109374. doi:10.1016/j.celrep.2021.109374
- Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409-1439. doi:10.1152/physrev.00034.2006
- Muttenthaler M, King GF, Adams DJ, Alewood PF. Trends in peptide drug discovery. Nat Rev Drug Discov. 2021;20(4):309-325. doi:10.1038/s41573-020-00135-8
